Northland Capmk Weighs in on MiMedx Group Q1 Earnings

MiMedx Group, Inc. (NASDAQ:MDXGFree Report) – Northland Capmk issued their Q1 2025 earnings per share (EPS) estimates for MiMedx Group in a note issued to investors on Friday, December 27th. Northland Capmk analyst C. Byrnes forecasts that the company will post earnings of $0.05 per share for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.08 EPS and Q4 2025 earnings at $0.09 EPS.

Separately, StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $12.00.

Read Our Latest Stock Analysis on MDXG

MiMedx Group Stock Up 1.5 %

MDXG stock opened at $9.62 on Monday. The stock has a market capitalization of $1.41 billion, a P/E ratio of 17.49 and a beta of 1.98. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The firm has a 50-day moving average price of $8.51 and a 200-day moving average price of $7.20. MiMedx Group has a 12 month low of $5.47 and a 12 month high of $10.14.

Institutional Investors Weigh In On MiMedx Group

Several hedge funds have recently added to or reduced their stakes in MDXG. JPMorgan Chase & Co. increased its position in MiMedx Group by 265.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock valued at $1,757,000 after acquiring an additional 215,995 shares during the period. Principal Financial Group Inc. increased its holdings in MiMedx Group by 6.3% in the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock valued at $328,000 after purchasing an additional 3,292 shares during the period. SkyView Investment Advisors LLC raised its position in MiMedx Group by 30.0% during the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company’s stock worth $77,000 after purchasing an additional 3,000 shares during the last quarter. Barclays PLC lifted its holdings in MiMedx Group by 163.9% during the 3rd quarter. Barclays PLC now owns 262,449 shares of the company’s stock worth $1,550,000 after buying an additional 163,005 shares during the period. Finally, Orion Capital Management LLC grew its position in shares of MiMedx Group by 46.3% in the 3rd quarter. Orion Capital Management LLC now owns 11,700 shares of the company’s stock valued at $69,000 after buying an additional 3,700 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

About MiMedx Group

(Get Free Report)

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.

Further Reading

Earnings History and Estimates for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.